Gene expression profiling in breast cancer: Classification, prognostication, and prediction

The Lancet

Volumn 378, Issue 9805, 2011, Pages 1812-1823

  Reis Filho, Jorge S ^a   Pusztai, Lajos ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; PROTEIN; TAMOXIFEN; TOP2A PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CELL PROLIFERATION; DISTANT METASTASIS; DRUG RESPONSE; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ENRICHED BREAST CANCER; GENE EXPRESSION; GENE EXPRESSION PROFILING; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; LYMPH NODE; MICROARRAY ANALYSIS; MOLECULAR DIAGNOSIS; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 81555216077     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61539-0     Document Type: Review

References (88)

1. PM Ravdin, LA Siminoff, GJ Davis et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer J Clin Oncol 19 2001 980 991 (Pubitemid 32176272)
2. RW Carlson, BO Anderson, HJ Burstein et al. Invasive breast cancer J Natl Compr Canc Netw 5 2007 246 312
3. A Goldhirsch, JN Ingle, RD Gelber, AS Coates, B Thurlimann, HJ Senn Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 2009 1319 1329
4. A Goldhirsch, WC Wood, AS Coates, RD Gelber, B Thurlimann, HJ Senn Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 2011 1736 1747
5. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
6. S Gruvberger, M Ringner, Y Chen et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns Cancer Res 61 2001 5979 5984 (Pubitemid 32762524)
7. CM Perou, T Sorlie, MB Eisen et al. Molecular portraits of human breast tumours Nature 406 2000 747 752
8. T Sorlie, CM Perou, R Tibshirani et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 2001 10869 10874 (Pubitemid 32878711)
9. JS Reis-Filho, B Weigelt, D Fumagalli, C Sotiriou Molecular profiling: moving away from tumor philately Sci Transl Med 2 2010 47ps43
10. C Sotiriou, L Pusztai Gene-expression signatures in breast cancer N Engl J Med 360 2009 790 800
11. B Weigelt, FL Baehner, JS Reis-Filho The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade J Pathol 220 2010 263 280
12. T Iwamoto, L Pusztai Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data? Genome Med 2 2010 81
13. L Pusztai, K Broglio, F Andre, WF Symmans, KR Hess, GN Hortobagyi Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer J Clin Oncol 26 2008 4679 4683
14. Z Hu, C Fan, DS Oh et al. The molecular portraits of breast tumors are conserved across microarray platforms BMC Genomics 7 2006 96
15. JS Parker, M Mullins, MC Cheang et al. Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncol 27 2009 1160 1167
16. T Sorlie, R Tibshirani, J Parker et al. Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 2003 8418 8423 (Pubitemid 36842560)
17. LJ van 't Veer, H Dai, MJ van de Vijver et al. Gene expression profiling predicts clinical outcome of breast cancer Nature 415 2002 530 536 (Pubitemid 34130608)
18. Y Wang, JG Klijn, Y Zhang et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 2005 671 679 (Pubitemid 40260888)
19. C Sotiriou, P Wirapati, S Loi et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis J Natl Cancer Inst 98 2006 262 272 (Pubitemid 43264710)
20. S Paik, S Shak, G Tang et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2004 2817 2826 (Pubitemid 40051905)
21. A Prat, JS Parker, O Karginova et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer Breast Cancer Res 12 2010 R68
22. P Farmer, H Bonnefoi, V Becette et al. Identification of molecular apocrine breast tumours by microarray analysis Oncogene 24 2005 4660 4671 (Pubitemid 41032603)
23. AS Doane, M Danso, P Lal et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen Oncogene 25 2006 3994 4008 (Pubitemid 43990755)
24. B Weigelt, A Mackay, R A'Hern et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis Lancet Oncol 11 2010 339 349
25. A Mackay, B Weigelt, A Grigoriadis et al. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement J Natl Cancer Inst 103 2011 662 673
26. B Weigelt, L Pusztai, A Ashworth, JS Reis-Filho Challenges translating breast cancer gene signatures into the clinic Nat Rev Clin Oncol 2011 10.1038/nrclinonc.2011.125 published online Oct 30.
27. B Weigelt, JS Reis-Filho Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry Breast Cancer Res 12 suppl 4 2010 S5
28. C Kim, S Paik Gene-expression-based prognostic assays for breast cancer Nat Rev Clin Oncol 7 2010 340 347
29. MJ van de Vijver, YD He, LJ van't Veer et al. A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999 2009 (Pubitemid 35461656)
30. XJ Ma, R Salunga, S Dahiya et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer Clin Cancer Res 14 2008 2601 2608
31. XJ Ma, Z Wang, PD Ryan et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen Cancer Cell 5 2004 607 616 (Pubitemid 38748922)
32. R Liu, X Wang, GY Chen et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells N Engl J Med 356 2007 217 226 (Pubitemid 46143225)
33. J Toussaint, AM Sieuwerts, B Haibe-Kains et al. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues BMC Genomics 10 2009 424
34. S Paik, G Tang, S Shak et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 2006 3726 3734 (Pubitemid 46622311)
35. S Mook, MK Schmidt, G Viale et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study Breast Cancer Res Treat 116 2009 295 302
36. M Knauer, F Cardoso, J Wesseling et al. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature Br J Cancer 103 2010 1788 1793
37. C Desmedt, A Giobbie-Hurder, P Neven et al. The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial BMC Med Genomics 2 2009 40
38. M Dowsett, J Cuzick, C Wale et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study J Clin Oncol 28 2010 1829 1834
39. KS Albain, WE Barlow, S Shak for The Breast Cancer Intergroup of North America Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 2010 55 65
40. P Wirapati, C Sotiriou, S Kunkel et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures Breast Cancer Res 10 2008 R65
41. PE Colombo, F Milanezi, B Weigelt, JS Reis-Filho Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction Breast Cancer Res 13 2011 212
42. C Fan, DS Oh, L Wessels et al. Concordance among gene-expression-based predictors for breast cancer N Engl J Med 355 2006 560 569 (Pubitemid 44200649)
43. F Reyal, MH van Vliet, NJ Armstrong et al. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer Breast Cancer Res 10 2008 R93
44. C Desmedt, B Haibe-Kains, P Wirapati et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes Clin Cancer Res 14 2008 5158 5165
45. T Iwamoto, G Bianchini, D Booser et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer J Natl Cancer Inst 103 2011 264 272
46. M Buyse, S Loi, L van't Veer et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 98 2006 1183 1192 (Pubitemid 44390989)
47. C Desmedt, F Piette, S Loi et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series Clin Cancer Res 13 2007 3207 3214 (Pubitemid 46944903)
48. J Cuzick, M Dowsett, S Pineda et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer J Clin Oncol 2011 10.1200/JCO.2011.37.5824 published online Oct 11.
49. M Knauer, S Mook, EJ Rutgers et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer Breast Cancer Res Treat 120 2010 655 661
50. JM Bueno-de-Mesquita, WH van Harten, VP Retel et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) Lancet Oncol 8 2007 1079 1087 (Pubitemid 350182954)
51. RM Simon, S Paik, DF Hayes Use of archived specimens in evaluation of prognostic and predictive biomarkers J Natl Cancer Inst 101 2009 1446 1452
52. AV Ivshina, J George, O Senko et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer Cancer Res 66 2006 10292 10301 (Pubitemid 44799747)
53. C Liedtke, C Hatzis, WF Symmans et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer J Clin Oncol 27 2009 3185 3191
54. LA Habel, S Shak, MK Jacobs et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients Breast Cancer Res 8 2006 R25
55. G Tang, S Shak, S Paik et al. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20 Breast Cancer Res Treat 127 2011 133 142
56. G Tang, J Cuzick, C Wale et al. Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: a meta-analysis approach Proc Am Soc Clin Oncol 28 suppl 2010 abstr 509.
57. SS Badve, FL Baehner, RP Gray et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory J Clin Oncol 26 2008 2473 2481
58. FL Baehner, N Achacoso, T Maddala et al. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories J Clin Oncol 28 2010 4300 4306
59. DJ Dabbs, ME Klein, SK Mohsin, RR Tubbs, Y Shuai, R Bhargava High false-negative rate of HER2 quantitative reverse transcription polymerase chain reaction of the Oncotype DX test: an independent quality assurance study J Clin Oncol 2011 10.1200/JCO.2010.31.2835 published online Oct 11.
60. WF Symmans, C Hatzis, C Sotiriou et al. Genomic index of sensitivity to endocrine therapy for breast cancer J Clin Oncol 28 2010 4111 4119
61. AE Teschendorff, C Caldas A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer Breast Cancer Res 10 2008 R73
62. G Bianchini, Y Qi, RH Alvarez et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers J Clin Oncol 28 2010 4316 4323
63. SM Mahmoud, EC Paish, DG Powe et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer J Clin Oncol 29 2011 1949 1955
64. P Farmer, H Bonnefoi, P Anderle et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer Nat Med 15 2009 68 74
65. G Finak, N Bertos, F Pepin et al. Stromal gene expression predicts clinical outcome in breast cancer Nat Med 14 2008 518 527 (Pubitemid 351655218)
66. A Bergamaschi, E Tagliabue, T Sorlie et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome J Pathol 214 2008 357 367 (Pubitemid 351212391)
67. MP Jansen, JA Foekens, IL van Staveren et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling J Clin Oncol 23 2005 732 740 (Pubitemid 46224172)
68. S Loi, B Haibe-Kains, C Desmedt et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen BMC Genomics 9 2008 239
69. DS Oh, MA Troester, J Usary et al. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers J Clin Oncol 24 2006 1656 1664 (Pubitemid 46622136)
70. M Ayers, WF Symmans, J Stec et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer J Clin Oncol 22 2004 2284 2293 (Pubitemid 41115384)
71. JC Chang, EC Wooten, A Tsimelzon et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer Lancet 362 2003 362 369 (Pubitemid 36957839)
72. L Gianni, M Zambetti, K Clark et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer J Clin Oncol 23 2005 7265 7277 (Pubitemid 46202341)
73. KR Hess, K Anderson, WF Symmans et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer J Clin Oncol 24 2006 4236 4244 (Pubitemid 46630780)
74. K Iwao-Koizumi, R Matoba, N Ueno et al. Prediction of docetaxel response in human breast cancer by gene expression profiling J Clin Oncol 23 2005 422 431 (Pubitemid 46224217)
75. O Thuerigen, A Schneeweiss, G Toedt et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer J Clin Oncol 24 2006 1839 1845 (Pubitemid 46638981)
76. C Desmedt, A Di Leo, E de Azambuja et al. Multifactorial approach to predicting resistance to anthracyclines J Clin Oncol 29 2011 1578 1586
77. C Hatzis, L Pusztai, V Valero et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer JAMA 305 2011 1873 1881
78. P Borst, L Wessels Do predictive signatures really predict response to cancer chemotherapy? Cell Cycle 9 2010 4836 4840
79. L Ding, MJ Ellis, S Li et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft Nature 464 2010 999 1005
80. N Juul, Z Szallasi, AC Eklund et al. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials Lancet Oncol 11 2010 358 365
81. A Potti, HK Dressman, A Bild et al. Genomic signatures to guide the use of chemotherapeutics Nat Med 12 2006 1294 1300 (Pubitemid 44706932)
82. H Bonnefoi, A Potti, M Delorenzi et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial Lancet Oncol 8 2007 1071 1078 (Pubitemid 350182953)
83. KA Baggerly, KR Coombes Deriving chemosensitivity from cell lines: forensic bioinformatics and reproducible research in high-throughput biology Ann Appl Stat 3 2009 1309 1344
84. H Bonnefoi, A Potti, M Delorenzi et al. Retraction - validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial Lancet Oncol 12 2011 116
85. EA Musgrove, RL Sutherland Biological determinants of endocrine resistance in breast cancer Nat Rev Cancer 9 2009 631 643
86. M Dowsett, TO Nielsen, R A'hern et al. Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group J Natl Cancer Inst 2011 10.1093/jnci/djr393 published online Sept 29.
87. SA Aparicio, DG Huntsman Does massively parallel DNA resequencing signify the end of histopathology as we know it? J Pathol 220 2010 307 315
88. TJ Hudson, W Anderson, A Artez et al. International network of cancer genome projects Nature 464 2010 993 998